Payment overview · 2025
General Payments
$119.48
6 reported records · 3 companies
Healthcare provider profile · identity verified
Brandon K Cox, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONETA, VA · NPI 1629239959
Verified facts
What the public records show
CMS Open Payments records show Brandon K Cox, MD received $119.48 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 44.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.64 | 44.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.34 | 31.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.50 | 24.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $119.48 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.64 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.64 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 161 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
161 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 625 | 184 |
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 448 | 116 |
| Montelukast Sodium | Montelukast Sodium | 373 | 107 |
| Lisinopril | Lisinopril | 358 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 91 |
| Omeprazole | Omeprazole | 337 | 78 |
| Metformin Hcl Er | Metformin Hcl | 328 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 96 |
| Gabapentin | Gabapentin | 266 | 88 |
| Irbesartan | Irbesartan | 243 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 68 |
| Furosemide | Furosemide | 194 | 66 |
| Ezetimibe | Ezetimibe | 192 | 56 |
| Allopurinol | Allopurinol | 187 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 47 |
| Losartan Potassium | Losartan Potassium | 162 | 51 |
| Eliquis | Apixaban | 161 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 151 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 38 |
| Trazodone Hcl | Trazodone Hcl | 141 | 47 |
| Doxazosin Mesylate | Doxazosin Mesylate | 138 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 41 |
| Finasteride | Finasteride | 122 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 119 | 28 |
| Chlorthalidone | Chlorthalidone | 117 | 35 |
| Benazepril Hcl | Benazepril Hcl | 114 | 29 |
| Alendronate Sodium | Alendronate Sodium | 110 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 49 |
| Potassium Chloride | Potassium Chloride | 100 | 38 |
| Buspirone Hcl | Buspirone Hcl | 97 | 38 |
| Famotidine | Famotidine | 95 | 35 |
| Metformin Hcl | Metformin Hcl | 91 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 26 |
| Celecoxib | Celecoxib | 90 | 31 |
| Calcitriol | Calcitriol | 88 | 30 |
| Glimepiride | Glimepiride | 88 | 26 |
| Prednisone | Prednisone | 87 | 70 |
| Synthroid | Levothyroxine Sodium | 84 | 24 |
| Carvedilol | Carvedilol | 81 | 27 |
| Lovastatin | Lovastatin | 78 | 17 |
| Pregabalin | Pregabalin | 77 | 18 |
| Clonazepam | Clonazepam | 75 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 73 | 61 |
| Tramadol Hcl | Tramadol Hcl | 73 | 20 |
| Sertraline Hcl | Sertraline Hcl | 71 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 19 |
| Simvastatin | Simvastatin | 67 | 17 |
| Azelastine Hcl | Azelastine Hcl | 66 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 17 |
| Jardiance | Empagliflozin | 62 | 19 |
| Alprazolam | Alprazolam | 61 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 14 |
| Lorazepam | Lorazepam | 58 | 12 |
| Cefdinir | Cefdinir | 57 | 48 |
| Spironolactone | Spironolactone | 56 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 15 |
| Fluconazole | Fluconazole | 48 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 18 |
| Bupropion Xl | Bupropion Hcl | 47 | 16 |
| Valsartan | Valsartan | 45 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 13 |
| Methylprednisolone | Methylprednisolone | 44 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 13 |
| Mirtazapine | Mirtazapine | 42 | 15 |
| Valacyclovir | Valacyclovir Hcl | 40 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | 20 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 26 | 23 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Indapamide | Indapamide | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | 15 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Estradiol | Estradiol | 23 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 23 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Baclofen | Baclofen | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Prolia | Denosumab | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Tretinoin | Tretinoin | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $119.48 · 6 records | PFIZER INC. | ELIQUIS, FREESTYLE LIBRE 3, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error